{"id":"W4221019027","doi":"10.1007/s12325-022-02104-6","title":"Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Pfizer","keywords":"Infliximab; Medicine; Biosimilar; Inflammatory bowel disease; Internal medicine; Ulcerative colitis; Observational study; Adverse effect; Disease","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000933407,0.0002497125,0.0004348589,0.00009688003,0.0002033348,0.00001673052,0.000312984,0.0000536499,0.00003218771],"category_scores_gemma":[0.0002126756,0.000131371,0.00006571795,0.0002682468,0.0003595888,0.0001596295,0.0001090072,0.0005035621,1.060572e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007935574,"about_ca_system_score_gemma":0.0001972312,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.06272872,"about_ca_topic_score_gemma":0.2815277,"domain_scores_codex":[0.9965223,0.001628439,0.0008650996,0.0004947437,0.0002382909,0.0002511236],"domain_scores_gemma":[0.9977745,0.001151378,0.0004018491,0.0005525794,0.00007020913,0.00004948421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00936185,0.002077545,0.9838079,0.000001700804,0.0002904535,0.00002453439,0.001643586,0.0001440414,0.000006276488,0.000009274127,0.00005638928,0.002576399],"study_design_scores_gemma":[0.01300408,0.003568728,0.9806998,0.00001266221,0.00004873443,2.326662e-7,0.001736967,0.00001355168,0.000005058942,0.0001019974,0.0006373582,0.0001707993],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974795,0.0003379025,2.69046e-7,0.0002370916,0.0002413935,0.001326624,0.000347701,0.000009146944,0.00002036887],"genre_scores_gemma":[0.9989038,0.0001633106,0.00002479628,0.0006924599,0.000009332201,0.0001015986,0.00007401167,0.00001445841,0.00001624847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.218799,"threshold_uncertainty_score":0.9435127,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03858910153886844,"score_gpt":0.3536401462139039,"score_spread":0.3150510446750355,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}